An update on the pathogenesis and treatment of IgA nephropathy (Q37982634)

26 August 2017

title

An update on the pathogenesis and treatment of IgA nephropathy (English)

1 reference

26 August 2017

0 references

5

1 reference

26 August 2017

Joanna K Boyd

1

1 reference

26 August 2017

Chee K Cheung

series ordinal

2

1 reference

26 August 2017

Karen Molyneux

series ordinal

3

1 reference

26 August 2017

John Feehally

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

81

1 reference

26 August 2017

issue

9

1 reference

26 August 2017

page(s)

833-843

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2011.501

26 August 2017

exact match

0 references

cites work

Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

O-glycosylation of serum IgD in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

HLA has strongest association with IgA nephropathy in genome-wide analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Genome-wide association study identifies susceptibility loci for IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

The immune geography of IgA induction and function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Low antibody affinity restricted to the IgA isotype in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

T-cell homing receptor expression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Mammalian Toll-like receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Toll-like receptor 9 affects severity of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

External suppression causes the low expression of the Cosmc gene in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Serum IgA and macromolecular IgA reacting with mesangial matrix components

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Interactions of human mesangial cells with IgA and IgA-containing immune complexes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgA-containing immune complexes in the urine of IgA nephropathy patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

The IgA nephropathy treatment dilemma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Treatment of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

IgA nephropathy at two score and one.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Dietary fish oil supplementation in IgA nephropathy: a therapy in search of a mechanism?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Can a dysregulated mucosal immune system in IgA nephropathy be controlled by tonsillectomy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Kidney transplantation in patients with IgA mesangial glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Posttransplant recurrence of primary glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Probability, predictors, and prognosis of posttransplantation glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Steroids and recurrent IgA nephropathy after kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

TLR based therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Non-immunosuppressive treatment for IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.501

7 January 2021

Identifiers

DOI

10.1038/KI.2011.501

1 reference

Dimensions Publication ID

26 August 2017

1029954386

0 references

1 reference